CATX Quote, Financials, Valuation and Earnings

Outset Medical, Inc. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of -60.61%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Outset Medical, Inc.'s return on equity of -81.05%.

Perspective Therapeutics, Inc. has a consensus price target of $12.3077, signalling upside risk potential of 333.37%. On the other hand Outset Medical, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 151.61%. Given that Perspective Therapeutics, Inc. has higher upside potential than Outset Medical, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Outset Medical, Inc..

Perspective Therapeutics, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Outset Medical, Inc. has a beta of 2.074, suggesting its more volatile than the S&P 500 by 107.371%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Outset Medical, Inc. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Outset Medical, Inc. quarterly revenues of $29.4M. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Outset Medical, Inc.'s net income of -$17.8M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Outset Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 192.56x versus 0.93x for Outset Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of -862.39%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat VolitionRX Ltd.'s return on equity of --.

Perspective Therapeutics, Inc. has a consensus price target of $12.3077, signalling upside risk potential of 333.37%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 520.07%. Given that VolitionRX Ltd. has higher upside potential than Perspective Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Perspective Therapeutics, Inc.'s net income of -$26M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 192.56x versus 24.31x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of -1037.17%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Perspective Therapeutics, Inc. has a consensus price target of $12.3077, signalling upside risk potential of 333.37%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1776.6%. Given that Catheter Precision, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Perspective Therapeutics, Inc..

Perspective Therapeutics, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 192.56x versus 9.52x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -12425.36% compared to Perspective Therapeutics, Inc.'s net margin of 3.93%. Perspective Therapeutics, Inc.'s return on equity of -37.63% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Perspective Therapeutics, Inc. has a consensus price target of $12.3077, signalling upside risk potential of 333.37%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 114.35%. Given that Perspective Therapeutics, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Xtant Medical Holdings, Inc..

Perspective Therapeutics, Inc. has a beta of 1.182, which suggesting that the stock is 18.151% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Perspective Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Perspective Therapeutics, Inc. quarterly revenues are $209K, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Perspective Therapeutics, Inc.'s net income of -$26M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Perspective Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 68.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics, Inc. is 192.56x versus 0.76x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.